COMPARAISON D'UN TRAITEMENT PREDNISONE + CYCLOPHOSPHAMIDE VERSUS PREDNISONE + RITUXIMAB CHEZ DES PATIENTS ATTEINTS D'HEMOPHILIE ACQUISE

ETUDE PROSPECTIVE RANDOMISEE COMPARATIVE PREDNISONE/ CYCLOPHOSPHAMIDE VERSUS PREDNISONE/ RITUXIMAB AU COURS DE L'HEMOPHILIE ACQUISE - CREHA

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-003539-68-FR

Enrollment

164

Registered

2011-11-24

Start date

2012-02-09

Completion date

Unknown

Last updated

2021-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 14.1 Level: PT Classification code 10053745 Term: Acquired haemophilia System Organ Class: 10005329 - Blood and lymphatic system disorders

Interventions

Trade Name: MabThera Pharmaceutical Form: Solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: range Concentration numbe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 164 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 164

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

France

Contacts

Public ContactChloé CREHALET / Caroline BULTE

CHU-Hôpitaux de ROUEN

secretariat.DRC@chu-rouen.fr+33(0)2 32 88 82 65

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026